CALL/AMGEN/450/0.1/17.01.25 | Real-time BOERSE MUENCHEN 04:26:05 2024-06-10 am EDT | ||
| 0.141 EUR | -9.03% |
|
| Current month | -8.82% | ||
| 1 month | -0.64% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
AMGEN INC.
Latest news about AMGEN INC.
More news
| Date | Price | Change |
|---|---|---|
| 24-06-10 | 0.141 | -9.03% |
| 24-06-07 | 0.155 | -10.40% |
| 24-06-06 | 0.173 | -11.73% |
| 24-06-05 | 0.196 | +2.62% |
| 24-06-04 | 0.191 | +2.69% |
Real-time BOERSE MUENCHEN
Last update June 10, 2024 at 04:26 am EDT
More quotesStatic data
| Product type | Plain-Vanilla-Warrants |
|---|---|
| Buy / Sell | CALL |
| Underlying | AMGEN INC. |
| Issuer | Goldman Sachs |
| WKN | GQ9GLT |
| ISIN | DE000GQ9GLT8 |
| Date issued | 2024-02-19 |
| Strike | 450 $ |
| Maturity | 2025-01-17 (222 Days) |
| Parity | 10 : 1 |
| Emission price | 0.07 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 0.269 € |
|---|---|
| Lowest since issue | 0.052 € |
| Spread | 0.1 € |
| Spread % | 43.48% |
Company Profile
Amgen Inc. is one of the world's leading biotechnology groups. Net sales break down by source of revenue as follows:
- drug sales (94.2%): drugs for treating cancer, metabolic disorders, bone diseases, renal failure, hemophilia, etc.;
- other (5.8%): primarily royalties.
The United States account for 70.3% of net sales.
Sector
-
Consensus: Amgen Inc.
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
30
Last Close Price
305
USD
Average target price
316.3
USD
Spread / Average Target
+3.69%
- Stock Market
- Warrants
- Warrant
